IP Library Granted Patent US 7,064,140
Granted Patent B2
US 7,064,140 · App. 10/459,911 · Granted Jun 20, 2006

Synergistic combinations including N-acylated 4-Hydroxyphenylamine derivatives and caffeine

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,064,140
App. No.
10/459,911
Granted
Jun 20, 2006
Kind
B2
Abstract

The present invention relates to pharmaceutical combinations of opioid and non-opioid analgesics in an intimate admixture with caffeine and an analgesic from a series of N-acylated 4-hydroxyphenylamine derivatives, linked via an alkylene bridge to the nitrogen atom of a 1,2-benzisothiazol-3(2H)-one 1,1-dioxide group and methods for their use to alleviate pain in mammals. The analgesic combinations exhibit enhanced analgesic potency and are free from antipyretic activity, do not suppress blood coagulation, and have little hepatotoxic effect.

Claims (46)

1. An analgesic composition comprising synergistic, safe, and pharmaceutically effective amounts of:

(a) an opioid analgesic;

(b) a non-narcotic analgesic of the general formula,

wherein n is a number from 1 to 5;

(c) caffeine; and

(d) a pharmaceutically acceptable carrier.

2. A composition according to claim 1 , wherein the opioid analgesic is a phenanthrene alkaloid of opium.

3. A composition according to claim 1 , wherein the opioid analgesic is selected from the group consisting of morphine and codeine.

4. A composition according to claim 1 , wherein the opioid analgesic is selected from the group consisting of hydrocodone, oxycodone, hydromorphone, oxymorphone, metopon, apomorphine, normorphine, and N-(2-phenylethyl)-normorphine.

5. A composition according to claim 1 , wherein the opioid analgesic is selected from the group consisting of etorphine and buprenorphine.

6. A composition according to claim 1 , wherein the opioid analgesic is selected from the group consisting of dextromethorphan, butorphanol, levorphanol, levallorphan, cyclorphan, and racemorphan.

7. A composition according to claim 1 , wherein the opioid analgesic is selected from the group consisting of phenazocine, pentazocine, and cylcazocine.

8. A composition according to claim 1 , wherein the opioid analgesic is selected from the group consisting of meperidine, anileridine, piminodine, ethoheptazine, alphaprodine, betaprodine, diphenoxylate, loperamide, fentanil, sufentanil, alfentanil, and remifentanil.

9. A composition according to claim 1 , wherein the opioid analgesic is selected from the group consisting of methadone, isomethadone, and propoxyphene.

10. An analgesic composition comprising synergistic, safe, and pharmaceutically effective amounts of:

(a) a non-opioid analgesic;

(b) a non-narcotic analgesic of the general formula,

wherein n is a number from 1 to 5;

(c) caffeine; and

(d) a pharmaceutically acceptable carrier.

11. A composition according to claim 10 , wherein the non-opioid analgesic is an NMDA receptor antagonist.

12. A composition according to claim 10 , wherein the non-opioid analgesic is selected from the group consisting of dextromethorphan and ketamine.

13. A composition according to claim 10 , wherein the non-opioid analgesic is an alpha 2 adrenoreceptor agonist.

14. A composition according to claim 10 , wherein the non-opioid analgesic is selected from the group consisting of clonidine, metomidine, detomidine, dexmetomidine, dexmedetomidine and xylazine.

15. A composition according to claim 10 , wherein the non-opioid analgesic is a monoamine re-uptake inhibitor.

16. A composition according to claim 10 , wherein the non-opioid analgesic is tramadol.

17. A composition according to claim 10 , wherein the non-opioid analgesic is a mixed agonist-antagonist analgesic.

18. A composition according to claim 10 , wherein the non-opioid analgesic is selected from the group consisting of buprenorphine, dezocine and nalbuphine.

19. A method of alleviating pain in a mammal which comprises administering to said mammal affected with pain an effective amount of the composition of claim 1 .

20. A method of alleviating pain in a mammal which comprises administering to said mammal affected with pain an effective amount of the composition of claim 2 .

21. A method of alleviating pain in a mammal which comprises administering to said mammal affected with pain an effective amount of the composition of claim 3 .

22. A method of alleviating pain in a mammal which comprises administering to said mammal affected with pain an effective amount of the composition of claim 4 .

23. A method of alleviating pain in a mammal which comprises administering to said mammal affected with pain an effective amount of the composition of claim 5 .

24. A method of alleviating pain in a mammal which comprises administering to said mammal affected with pain an effective amount of the composition of claim 6 .

25. A method of alleviating pain in a mammal which comprises administering to said mammal affected with pain an effective amount of the composition of claim 7 .

26. A method of alleviating pain in a mammal which comprises administering to said mammal affected with pain an effective amount of the composition of claim 8 .

27. A method of alleviating pain in a mammal which comprises administering to said mammal affected with pain an effective amount of the composition of claim 9 .

28. A method of alleviating pain in a mammal which comprises administering to said mammal affected with pain an effective amount of the composition of claim 10 .

29. A method of alleviating pain in a mammal which comprises administering to said mammal affected with pain an effective amount of the composition of claim 11 .

30. A method of alleviating pain in a mammal which comprises administering to said mammal affected with pain an effective amount of the composition of claim 12 .

31. A method of alleviating pain in a mammal which comprises administering to said mammal affected with pain an effective amount of the composition of claim 13 .

32. A method of alleviating pain in a mammal which comprises administering to said mammal affected with pain an effective amount of the composition of claim 14 .

33. A method of alleviating pain in a mammal which comprises administering to said mammal affected with pain an effective amount of the composition of claim 15 .

34. A method of alleviating pain in a mammal which comprises administering to said mammal affected with pain an effective amount of the composition of claim 16 .

35. A method of alleviating pain in a mammal which comprises administering to said mammal affected with pain an effective amount of the composition of claim 17 .

36. A method of alleviating pain in a mammal which comprises administering to said mammal affected with pain an effective amount of the composition of claim 18 .

Assignments (4)
CONFIRMATORY LICENSE Recorded Jul 10, 2015
From: LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER
To: NATIONAL SCIENCE FOUNDATION
Reel/Frame 036092/0772 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 2, 2008
From: BAZAN, NICOLAS G.; PAUL, DENNIS; SUNKEL, CARLOS; ALVAREZ-BUILLA, JULIO; THE FOUNDATION FOR THE LSU HEALTH SCIENCES CENTER; LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER NEW ORLEANS
To: BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE
Reel/Frame 021187/0957 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 26, 2006
From: FOUNDATION FOR THE LSU HEALTH SCIENCES CENTER
To: BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE
Reel/Frame 017833/0806 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 26, 2006
From: BAZAN, NICOLAS G.; PAUL, DENNIS; ALVAREZ-BUILLA, JULIO; SUNKEL, CARLOS
To: LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER NEW ORLEANS
Reel/Frame 017688/0353 →
Continuity (2)
Continuation In Part 1029210500 · Nov 12, 2002
Related Publication 20040254207A1 · Dec 16, 2004